NanoViricides Inc (NYSEAMERICAN:NNVC) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 269,581 shares, an increase of 29.0% from the August 15th total of 208,910 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 197,664 shares, the short-interest ratio is currently 1.4 days.

NanoViricides stock traded down $0.03 during midday trading on Wednesday, hitting $0.38. 188,328 shares of the company’s stock were exchanged, compared to its average volume of 137,252. NanoViricides has a 12 month low of $0.25 and a 12 month high of $1.40.

A hedge fund recently raised its stake in NanoViricides stock. Renaissance Technologies LLC boosted its holdings in shares of NanoViricides Inc (NYSEAMERICAN:NNVC) by 67.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 888,372 shares of the company’s stock after acquiring an additional 356,872 shares during the period. Renaissance Technologies LLC owned about 1.29% of NanoViricides worth $391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About NanoViricides

NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS.

Read More: What does relative strength index mean?

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.